Receptor News and Research

RSS

Do GLP-1 drugs cause cancer? New review says no, may even protect

A comprehensive review in The Journal of Clinical Investigation finds no overall link between GLP-1 receptor agonists and increased cancer risk, countering early safety concerns. Instead, evidence suggests possible protective effects for certain cancers, supported by metabolic and immune-modulating mechanisms.

4 Nov 2025

GLP-1 drugs calm inflammation beyond diabetes and weight loss

This Journal of Clinical Investigation review describes how glucagon-like peptide-1 (GLP-1)–based medicines reduce systemic and tissue inflammation through both weight-dependent and weight-independent mechanisms. It details preclinical and clinical evidence linking GLP-1 receptor activation to cardiovascular, renal, hepatic, neural, and joint anti-inflammatory effects while outlining uncertainties and future research needs.

4 Nov 2025

Stress hormones may silence crucial neuronal genes through specific RNA molecules

What if the brain's response to stress could be read not in fleeting neurotransmitter bursts, but in the quieting of genes deep inside chromatin? Researchers at the University of Alabama at Birmingham have now shown that stress hormones may silence crucial neuronal genes through an unexpected class of RNA molecules that operate not by encoding proteins, but by reshaping the genome's architecture.

4 Nov 2025

Heated tobacco and cigarettes cause the same gut and vascular damage, study finds

Italian researchers found that both heated tobacco products (HTPs) and conventional cigarettes trigger oxidative stress, endotoxemia, and gut barrier disruption in adults and children. The findings challenge the perception that HTPs are a safer alternative to smoking.

3 Nov 2025

Healthy lifestyle habits plus GLP-1 RA drugs can improve heart health of people with Type 2 diabetes

People with Type 2 diabetes who combined healthy lifestyle habits with GLP-1 receptor agonist (GLP-1 RA) medications had a greater reduction in risk of major adverse cardiovascular events, including heart attack, stroke or cardiovascular disease death, compared to people only taking the medication, according to a preliminary study to be presented at the American Heart Association's Scientific Sessions 2025.

3 Nov 2025

New research reveals how human astroviruses enter the body

Human astroviruses are a leading viral cause of the stomach bug-think vomiting, diarrhea, and fever. It often impacts young children and older adults, leading to vicious cycles of sickness and malnutrition, particularly for those in low and middle income countries.

3 Nov 2025

Scientists uncover new obesity genes that reshape understanding of weight and disease risk

Researchers identified five previously unknown genes linked to obesity by analyzing rare protein-truncating variants across six ancestries. The study reveals how rare and common genetic factors combine to influence BMI and related diseases like diabetes and heart failure.

2 Nov 2025

Molecular bumpers and glues rewire GPCR signaling for next-generation medicines

New research led by the University of Minnesota Medical School demonstrates that molecules acting as "molecular bumpers" and "molecular glues" can rewire G protein-coupled receptor (GPCR) signaling, turning the cell's busiest receptors into precision tools - opening the door to a new generation of safer, smarter medicines.

31 Oct 2025

Immune cell dysregulation and inflammatory mediators shape epilepsy risk

Emerging evidence implicates immune dysregulation and neuroinflammation in the pathogenesis of epilepsy, yet the causal mechanisms remain unclear.

31 Oct 2025

Mutated RIG-I receptor causes kidney inflammation through Y-RNA activation

Researchers at the University Hospital Bonn (UKB) and the University of Bonn have discovered how a small, naturally occurring RNA molecule in the kidney activates a mutated immune receptor, triggering a chain reaction.

31 Oct 2025

Breakthrough study maps impact of thousands of variants in heart disease gene

An international research consortium co-led by scientists from Vanderbilt University Medical Center, the University of Toronto and University of Pittsburgh has mapped the functional impact of more than 17,000 variants in a major gene associated with the development of premature atherosclerotic heart disease.

31 Oct 2025

First-of-its-kind resource created to identify people with genetic risk for elevated 'bad' cholesterol

An international team led by a University of Pittsburgh School of Medicine scientist has created a first-of-its-kind resource to identify those with a genetic risk for elevated 'bad' cholesterol -- a major contributor to heart disease.

30 Oct 2025

Fundamental challenges and cutting-edge strategies in developing new GBM CAR-T therapies

Glioblastoma (GBM), the most aggressive primary brain tumor, continues to portend a poor prognosis with median survival under two years, despite standard care involving surgery, radiation, and temozolomide chemotherapy.

30 Oct 2025

Breakthrough could offer a new therapeutic option for stopping diabetes-induced complications

Researchers from the University at Albany and NYU Grossman School of Medicine have found a way to block a key cellular pathway known to drive chronic inflammation and impaired wound healing in people with diabetes.

30 Oct 2025

Research identifies biomarkers in blood to fine-tune breast cancer interventions

Doctors may be able to spare patients unnecessarily aggressive breast cancer treatments by collecting and testing cancer cells in patients' blood, research from the University of Michigan and the University of Kansas suggests.

30 Oct 2025

WHO reviews highlight limited long-term data on GLP-1 drug safety

Three new Cochrane reviews find evidence that GLP-1 drugs result in clinically meaningful weight loss, but industry-funded studies raise questions. The reviews were commissioned by the World Health Organization (WHO) to inform upcoming guidelines on the use of these drugs to treat obesity.

30 Oct 2025

Diabetes remission possible with GLP-1 drugs, Italian study confirms

In a large real-world Italian cohort, GLP-1 receptor agonist therapy led to measurable rates of type 2 diabetes remission, depending on how remission was defined. The most pragmatic definition (Remission 3) was linked to improved glycemia, weight, and a lower risk of microvascular and cardiovascular events.

29 Oct 2025

Systematic analysis reveals psilocybin's impact on obsessive-compulsive behaviors

A systematic review published today in Psychedelics by Mr. James Gattuso and colleagues at the Florey Institute of Neuroscience and Mental Health synthesizes clinical and preclinical evidence on psilocybin's effects on obsessive-compulsive behaviors, revealing consistent therapeutic potential across human patients and validated animal models.

29 Oct 2025

AI indelibly transforms solid tumor drug development

Artificial intelligence (AI) is fundamentally reshaping the landscape of solid tumor (ST) drug development.

29 Oct 2025

Specialized type of cardiac fibroblasts can actively worsen heart failure

Heart failure (HF) is one of the leading causes of death and disability worldwide, affecting millions of people and placing an enormous burden on healthcare systems.

29 Oct 2025

Receptor News and Research

Do GLP-1 drugs cause cancer? New review says no, may even protect

GLP-1 drugs calm inflammation beyond diabetes and weight loss

Stress hormones may silence crucial neuronal genes through specific RNA molecules

Heated tobacco and cigarettes cause the same gut and vascular damage, study finds

Healthy lifestyle habits plus GLP-1 RA drugs can improve heart health of people with Type 2 diabetes

New research reveals how human astroviruses enter the body

Scientists uncover new obesity genes that reshape understanding of weight and disease risk

Molecular bumpers and glues rewire GPCR signaling for next-generation medicines

Immune cell dysregulation and inflammatory mediators shape epilepsy risk

Mutated RIG-I receptor causes kidney inflammation through Y-RNA activation

Breakthrough study maps impact of thousands of variants in heart disease gene

First-of-its-kind resource created to identify people with genetic risk for elevated 'bad' cholesterol

Fundamental challenges and cutting-edge strategies in developing new GBM CAR-T therapies

Breakthrough could offer a new therapeutic option for stopping diabetes-induced complications

Research identifies biomarkers in blood to fine-tune breast cancer interventions

WHO reviews highlight limited long-term data on GLP-1 drug safety

Diabetes remission possible with GLP-1 drugs, Italian study confirms

Systematic analysis reveals psilocybin's impact on obsessive-compulsive behaviors

AI indelibly transforms solid tumor drug development

Specialized type of cardiac fibroblasts can actively worsen heart failure

Lab Matters host Harriet Gould on building a more connected lab community

The Critical Role of Sample Storage in Drug Discovery and Development

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

Latest News